Protocols

Bluebird says EMA has begun reviewing its LentiGlobin gene therapy; Sarepta bags rights to neuropathy gene therapy

→ Bluebird Bio says that its European application for LentiGlobin, its gene therapy for transfusion-dependent β-thalassemia, has made it through the doors at the EMA. The acceptance sets up a marketing decision for this therapy as the biotech plots a shift to commercialization work.

→ Sarepta is all in on gene therapies. Banking on early but notable successes for its Duchenne MD program, Sarepta is following up with its partners at Nationwide Children’s Hospital to gain rights to the gene therapy candidate, neurotrophin 3, to treat Charcot-Marie-Tooth neuropathies, including CMT type 1A.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->